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Pregnancy is a state of partial immune suppression which makes 
pregnant women more vulnerable to viral infections, and the mor-
bidity is higher even with seasonal influenza. Therefore, the COVID-
19 epidemic may have serious consequences for pregnant women. 
Although the vast majority of cases of COVID-19 are currently in 
China, the risk of outward transmission appears to be significantly 
raising global concern. Human to human transmission of the virus is 
proven to occur,1,2 perhaps even from asymptomatic patients,3,4 and 
the mortality is substantial, especially among frail, elderly patients 
with comorbidities.5 Although there have been some criticisms sur-
rounding suppression of early warnings, and slow initial response 
followed by heavy-handed quarantine measures, as well as con-
cerns expressed about the capacity to cope with the large number 
of patients, and shortage of protective equipment and in-hospital 
infections leading to deaths among a substantial number of health-
care professionals,6,7 China's effort to contain the disease and slow 
down its spread in China and world-wide has been commendable. A 
large number of cases requiring hospitalization and intensive care 
is a serious burden even for affluent countries with well-developed 
healthcare systems. However, the Chinese government, its health 
professionals, and the public, have set a new standard for handling 
the epidemic, and they have certainly contributed to reducing the 
potential risk of outbreak in neighboring countries with weaker 
healthcare systems. Furthermore, Chinese researchers and health 
professionals have generously shared their data, knowledge, expe-
rience and expertise that has helped to develop diagnostic tools, 
clinical management algorithms, set up clinical trials, and accelerate 
vaccine development. Clinical course and outcome of a substantial 
number of COVID-19 patients have been reported, and recommen-
dations regarding the care of such patients have been issued by 
several national health authorities across the world. However, the 
practices seem to vary considerably.
Interim guidance has been issued by the World Health 
Organization (WHO) and Centers for Disease Control and Prevention 
(CDC) on managing COVID-19, which include some recommen-
dations specific to pregnant women, mostly drawn on experience 
from previous coronavirus outbreaks.8,9 Chinese expert recommen-
dations for the care of pregnant women with suspected and con-
firmed COVID-9 were developed and disseminated in China quite 
early following the outbreak in Wuhan.10 These recommendations 
have been dynamic, evolving as more knowledge about epidemiol-
ogy, pathogenesis, disease progression and clinical course among 
infected pregnant patients has been gathered. Limited clinical expe-
rience in managing pregnant women with COVID-19 and their neo-
nates has been reported from China recently based on a case series 
of nine pregnancies with confirmed COVID-19 treated in Zhongnan 
Hospital of Wuhan University and 10 neonates (nine pregnancies) 
delivered at five different hospitals,11,12 although many more cases 
(>100) of suspected or confirmed COVID-19 have been treated and 
delivered in several hospitals in China according to the news releases 
and media reports. So far, no maternal deaths have been reported.
There appears to be some risk of premature rupture of mem-
branes, preterm delivery, fetal tachycardia and fetal distress when 
the infection occurs in the third trimester of pregnancy. However, 
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there is no evidence suggesting transplacental transmission based 
on very limited data, as the analysis of amniotic fluid, cord blood, 
neonatal throat swab, and breast milk samples available from six 
of the nine patients were found to be negative for SARS-COV-2. 
Whether virus shedding occurs vaginally is also not known.
Whether COVID-19 increases the risk of miscarriage and still-
birth is unknown. Concerns have been expressed by experts in the 
media about women undergoing termination of pregnancy for fear 
of congenital infection and teratogenicity. However, information on 
the effect of COVID-19 on the course and outcome of pregnancy in 
the first and second trimesters is not available yet.
As COVID-19 still appears to be spreading, more infections in 
pregnant women are likely to be encountered in different regions, 
countries, and continents. Therefore, it is important that pregnant 
women and their families, as well as the general public and health-
care providers, receive as accurate information as possible. Here is 
our attempt to summarize some important practical clinical aspects 
of managing COVID-19 in pregnancy:
2  | PRE VENTION
Incubation period of COVID19 is about 2-14 days, but infected per-
sons can transmit the virus via close contact and respiratory drop-
lets perhaps even before they become symptomatic. Physiological 
changes in the immune and respiratory system may make pregnant 
women more susceptible to COVID-19 infection during the epi-
demic. No effective vaccine is available at present. Therefore, it is 
advisable that pregnant women refrain from unnecessary travel, 
avoid crowds, public transport, contact with sick people, and more 
importantly, practice and maintain good personal and social hygiene. 
Pregnant women with symptoms of fever, cough, fatigue, myalgia, 
sore throat or shortness of breath should seek timely medical con-
sultation and help. Women with a travel history to endemic areas 
and those with a clinical suspicion of infection should be isolated 
and investigated. Some pregnant women may develop severe anxi-
ety and depression requiring professional psychological support to 
prevent adverse outcomes.
3  | DIAGNOSIS
The main clinical manifestations are fever, fatigue, myalgia, dry 
cough, and shortness of breath. Few patients may present with nasal 
congestion, runny nose, sore throat, hemoptysis, or diarrhea.
Peripheral white blood cells count is normal or decreased 
in early stages, and the lymphocyte count may be reduced. 
C-reactive protein may be increased. Some patients may have mild 
thrombocytopenia, elevated levels of liver enzymes and creatine 
phosphokinase.
A computed tomography (CT) scan of the chest without contrast 
is the most useful investigation to confirm or rule out viral pneu-
monia, and should be performed in suspected cases as the risk of 
radiation exposure to the fetus is very small. In a recent report, sen-
sitivity of chest CT in diagnosing COVID-19 was shown to be greater 
than that of RT-PCR (98% vs 71%).13 Radiological signs of viral pneu-
monia were present in an overwhelming majority of reported preg-
nancies with COVID-19 infection.
SARS-COV-2 is the etiologic agent of COVID-19, and its viral 
nucleic acid detection using real-time polymerase chain reaction 
(RT-PCR) is considered the reference standard for the diagnosis. 
Specimens should be obtained from saliva, upper respiratory tract 
(nasopharyngeal and oropharyngeal swabs), lower respiratory 
tract (sputum, endotracheal aspirate, or bronchoalveolar lavage), 
urine and stool if possible. Repeated testing may be required 
to confirm the diagnosis. If the SARS-COV-2 nucleic acid is not 
detected in respiratory tract samples taken on two consecutive 
occasions at least 24 hours apart, COVID-19 can be ruled out. 
Serology as a diagnostic procedure should be used only if RT-PCR 
is not available.
To screen for other respiratory infections, samples should also 
be tested for other viruses (such as influenza virus A and B, adeno-
virus, respiratory syncytial virus, rhinovirus, human metapneumo-
virus, SARS-CoV), bacterial pneumonia, chlamydia and mycoplasma 
pneumoniae.
It is important to take blood cultures for bacteria that cause 
pneumonia and sepsis ideally before initiating antimicrobial therapy.
4  | MANAGEMENT
Pregnant women suspected of COVID-19 should be isolated and 
investigated. Those diagnosed with infection should be promptly 
admitted to a negative pressure isolation ward, preferably in a des-
ignated hospital with adequate facilities and multi-disciplinary ex-
pertise to manage critically ill obstetric patients. They should be 
triaged and stratified into mild (symptomatic patient with stable vital 
signs), severe (respiration rate ≥30/min, resting SaO2 ≤93%, arterial 
blood oxygen partial pressure (PaO2)/ oxygen concentration (FiO2) 
≤300 mmHg) or critical (shock with organ failure, respiratory failure 
requiring mechanical ventilation or refractory hypoxemia requiring 
extra-corporal membrane oxygenation) categories based on clinical 
evaluation, and managed by a multidisciplinary team of midwife, ob-
stetrician, specialist in intensive care medicine, microbiologist, an-
esthetist and neonatologist. All medical staff caring for COVID-19 
patients should use personal protective equipment including gown, 
N95 masks, goggles, and gloves. Special consideration should be 
given to physiological adaptations in pregnancy when treating preg-
nant women with COVID-19 infection.
4.1 | Supportive therapy
Adequate rest, hydration, nutritional support, and water and electro-
lyte balance should be ensured. It is essential to monitor vital signs 
and oxygen saturation closely. Depending on the severity of the 
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disease, supplemental oxygen inhalation (60%-100% concentration 
at a rate of 40 L/min) should be given via high-flow nasal cannula 
depending on the severity of hypoxemia. Intubation and mechanical 
ventilation or even extra-corporal membrane oxygenation (ECMO) 
may be required to maintain oxygenation. Other complications may 
include septic shock, acute kidney injury, and virus-induced cardiac 
injury. Therefore, it is important to check arterial blood gases, lactate, 
renal function, liver function and cardiac enzymes as indicated by the 
clinical situation.
4.2 | Antiviral treatment
Antiviral treatment has been routinely used to treat COVID-19 in-
fection in China, and is also recommended for pregnant patients. 
Combination therapy with antiproteases Lopinavir/Ritonavir has 
been the preferred drug regimen as it is known to be relatively safe 
in pregnancy. The recommended dose is two capsules of Lopinavir/
Ritonavir (200 mg/50 mg per capsule) orally together with nebulized 
α-interferon inhalation (5 million IU in 2 mL of sterile water for injec-
tion) twice a day.
WHO advises caution and careful risk-benefit analysis before 
using investigational therapeutic agents in pregnant women outside 
clinical trials. Remdesivir, a nucleotide analog, and chloroquine, an 
antimalarial drug, are promising drugs against COVID-19 as they are 
known to inhibit SARS-COV-2 virus in vitro.14 Clinical trials have al-
ready started in China and are planned elsewhere.
4.3 | Antibacterial treatment
The extensive lung damage by the virus substantially increases the 
risk of secondary bacterial pneumonia. Antibiotics are indicated 
only if there is evidence of secondary bacterial infection. However, 
antibiotics should be administered without delay if bacterial sepsis 
is suspected. Intravenous Ceftriaxone can be administered initially 
while awaiting culture and sensitivity results.
4.4 | Corticosteroid therapy
In general, use of corticosteroids in the treatment of COVID-19 
pneumonia is not recommended as it may delay the virus clearance 
from the body. However, short-term (3-5 days) administration of 
methylprednisolone (1-2 mg/Kg bodyweight per day) has been used 
frequently in China, especially when dyspnea and hypoxemia are 
severe, in an attempt to ameliorate lung inflammation and prevent 
acute respiratory distress syndrome. This regimen is also recom-
mended for pregnant women with COVID-19, although data on its 
effectiveness and safety need further evaluation. Administration 
of Betamethasone 12mg intramuscularly followed by another dose 
24 hours later should be considered to promote fetal lung maturity 
when preterm delivery is anticipated.
5  | TIMING AND MODE OF DELIVERY
Timing of delivery should be individualized based on disease sever-
ity, existing comorbidities such as preeclampsia, diabetes, cardiac 
disease etc, obstetric history, and gestational age and fetal condi-
tion. In mild and stable cases responding to treatment and in the 
absence of fetal compromise, pregnancy may be continued to term 
under close surveillance. Regular monitoring of maternal vital signs 
(temperature, heart rate, blood pressure, respiration rate and oxy-
gen saturation by pulse-oximetry). Dynamic assessment of electro-
lytes and fluid balance, arterial blood gases, and acid-base status is 
required. Ultrasound examination of the fetus and fetal heart rate 
monitoring are recommended to assess fetal wellbeing.
In critical cases, continuing pregnancy may endanger the safety 
of the mother and her fetus. In such situations, delivery may be in-
dicated even if the baby is premature, and termination of pregnancy 
should be considered as an option before fetal viability is reached in 
order to save the pregnant woman's life after careful consultation 
with the patient, her family and an ethical board.
Mode of delivery is mainly determined by obstetric indications. 
Careful consideration should be given in regards to choice of anes-
thesia when a delivery by cesarean section is required. In two pub-
lished reports from China involving a total of 18 pregnant women 
with COVID-19, all but two were delivered by cesarean section, and 
none of the neonates were infected by SARS-COV-2. As the of evi-
dence for vaginal shedding of virus and vertical transmission is lack-
ing, vaginal delivery may be considered in stable patients.
6  | C ARE OF THE NE WBORN
Limited data obtained from cases of pregnant women with COVID-
19 suggest that the transplacental transmission is unlikely in late 
pregnancy close to term, as the virus was not identified in the amni-
otic fluid, placenta, breast milk of these mothers or in the nasal se-
cretions of their neonates. However, infection can occur in neonates 
via close contact. Two such cases of neonatal COVID-19 infection 
have been confirmed so far at 36 hours and 17 days after birth, and 
both appear to have been infected postnatally.15
Therefore, early cord clamping and temporary separation of the 
newborn for at least 2 weeks is recommended to minimize the risk of 
viral transmission by avoiding longer, close contact with the infected 
mother. The neonate should be cared for in an isolation ward and 
carefully monitored for any signs of infection. During this period, 
direct breast feeding is not recommended. A possible option is for 
the mother to pump her breast milk, which can be fed to the baby by 
a healthy caregiver.9
7  | CONCLUSIONS
As the COVID-19 epidemic continues to spread around the world, 
we need to plan and prepare ourselves proactively. Providing 
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appropriate clinical management and support to patients while ad-
equately protecting healthcare professionals should be our goal. A 
multi-disciplinary team approach should be adopted in managing 
these patients as it allows to effectively share the expertise as well 
as responsibility, and treat our patients with dignity and compassion. 
However, there are many challenges to overcome, such as shortage 
of protective equipment, depleting supply of medicines and blood 
products (reduced blood donations), infected pregnant women 
showing up directly to delivery rooms in advanced labor, psycho-
logical pressure and panic, just to mention a few. In hospitals, the 
transmission of the virus and deaths among healthcare professionals 
are serious concerns. Improving healthcare governance, as well as 
supporting, educating and training healthcare personnel in infection 
control and self-protection need to be prioritized. Clinical recom-
mendations for managing COVID-19 infection in pregnancy should 
be based on data from the current epidemic rather than drawing on 
limited experience from previous outbreaks of different types of co-
rona viruses, as their epidemiology, clinical course and response to 
treatment may differ. Guidelines will evolve as more data become 
available and experience is gathered. Therefore, complete data on 
all pregnancies affected by COVID-19 should be collected and made 
publicly available. Sharing data, knowledge and expertise, and help-
ing countries with poor resources and weaker healthcare systems 
are important in this respect.
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